openPR Logo
Press release

Investigation announced for Investors in shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

02-03-2020 04:13 PM CET | Politics, Law & Society

Press release from: Shareholders Foundation

An investigation for investors in AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares over potential securities laws violations.

An investigation for investors in AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares over potential securities laws violations.

An investigation was announced concerning potential securities laws violations by AMAG Pharmaceuticals, Inc. in connection with certain financial statements.

Investors who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on whether a series of statements by AMAG Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Waltham MA based AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. AMAG Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $609.94 million in 2017 to $474 million in 2018 and that its Net Loss declined from $199.22 million in 2017 to $65.76 million in 2018.

On October 29, 2019, AMAG Pharmaceuticals, Inc. announced that the Food and Drug Administration's ("FDA") Bone, Reproductive and Urologic Drugs Advisory Committee had voted 16-0 that the Company's confirmatory study, Trial 003, failed to demonstrate the effectiveness of AMAG's Makena product in reducing the risk of preterm births in women with histories of singleton spontaneous preterm birth. The FDA committee also voted 13-3 that the clinical data (Trials 002 and 003) in the Company's application failed to demonstrate substantial evidence of effectiveness.

Shares of AMAG Pharmaceuticals, Inc.(NASDAQ: AMAG) declined from $$13.33 per share on October 29, 2019 to as low as $8.92 per share on November 6, 2019.

Then, on January 9, 2020, AMAG Pharmaceuticals, Inc. disclosed plans to divest its Intrarosa and Vyleesi products in order to lower operating expenses. Concurrently, AMAG announced that William Heiden would step down as AMAG's President and Chief Executive Officer following the appointment of a successor by the Company's Board of Directors.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) declined from $$12.79 per share on December 26, 2019 to as low as $8.99 per share on January 30, 2020.

Those who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) here

News-ID: 1917092 • Views: 396

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Airbus SE (EADSY)
Airbus SE is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Airbus SE (EADSY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Airbus SE (EADSY regarding its business, its prospects and its operations were materially false and misleading at
Deadline in Lawsuit for Investors in shares of Portola Pharmaceuticals, Inc. (NA …
The Shareholders Foundation announced that a deadline is coming up on March 16, 2020in the lawsuit filed for certain investors of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) over alleged securities laws violations by Portola Pharmaceuticals, Inc. Investors who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and there are strict and short deadlines running. Deadline: March 16, 2020. NASDAQ: PTLA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or
Investigation announced for Investors in shares of Insperity, Inc. (NYSE: NSP)
An investigation was announced over possible violations of securities laws by Insperity, Inc. in connection with certain financial statements. Investors who purchased shares of Insperity, Inc. (NYSE: NSP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Insperity, Inc. regarding its business, its prospects and its operations were materially false
Investigation for Long-Term Investors in NASDAQ: MYGN shares over possible Wrong …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Myriad Genetics, Inc. Investors who are current long term investors in Myriad Genetics, Inc. (NASDAQ: MYGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: MYGN stocks follows a lawsuit filed against Myriad

All 5 Releases


More Releases for AMAG

Anemia Therapeutics Market Analysis Outlook (2019-2025)| AMAG Pharmaceuticals, D …
The research study presented here is a highly detailed and meticulous account of almost all key aspects of the global Anemia Therapeutics market. It digs deep into market dynamics including growth drivers, challenges, restraints, trends, and opportunities. Market players can use the research study to tighten their grip on the global Anemia Therapeutics market as they gain a sound understanding of market competition, regional growth, Anemia Therapeutics market segmentation, and
Intravenous Iron Drugs Market Key Players : Actavis, Inc., AMAG Pharmaceuticals, …
Iron is one of the most important mineral present inside the human body. It carries oxygen throughout the body via the blood, which is further utilized by cells and tissue to get energy for all vital biological processes. Moreover, deficiency of iron leads to severe health problems, such as anemia and also affects mental or other memory functions in youths. To overcome this problem, oral iron supplements are recommended to
New Research Study on Oral Mucositis Market | Top Players - Amag Pharmaceuticals …
HTF MI released a new market study on Global Oral Mucositis Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates
Global Anemia Treatment Market 2019 - AMAG Pharmaceuticals, Rockwell Medical, Ak …
Anemia is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood,[3][4] or a lowered ability of the blood to carry oxygen.[5] When anemia comes on slowly, the symptoms are often vague and may include feeling tired, weakness, shortness of breath or a poor ability to exercise. In 2018, the global Anemia Treatment market size was xx million US$ and it is expected to reach
Global Anodic Alumina Plate Market 2018 - Constellium, Norsk Hydro, AMAG, Toyal, …
Apex Market Reports, recently published a detailed market research study focused on the “Anodic Alumina Plate Market” across the global, regional and country level. The report provides 360° analysis of “Anodic Alumina Plate Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Anodic
Aluminum Extrusion Products Market 2017-Alcoa, Aleris, Kobelco, AMAG, RUSAL
Apex Market Reports, recently published a detailed market research study focused on the "Aluminum Extrusion Products Market" across the global, regional and country level. The report provides 360° analysis of "Aluminum Extrusion Products Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Aluminum Extrusion Products industry, and estimates the future trend of